Evaluation of Omalizumab Therapeutic Effects in Mild to Moderate Psoriatic Patients Resistant to Routine Topical Treatments

Mashhad University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新: 2023年10月16日

试验速览

暂无简介。

•Patients with mild to moderate psoriasis (with PASI more than 10-15 and less than 30-40) with more than 10-15% involvement and whose disease is not so mild and limited to respond to routine topical treatment (they have received routine topical treatment and have not reached the minimum acceptable therapeutic response*), And it was not so severe and extensive that needs severe stage treatments (with too many side effects). *Minimum acceptable therapeutic response: BSA less than 3% or BSA reduction greater than 75% (compared to the time of starting treatment) at 3 months after starting treatment.
•Patients living in remote area who cannot travel a long distance to receive phototherapy 3 times a week and for a long period of time.
•30-50 years old

•Prior history of Omalizumab injection
•Prior history of receiving systemic treatments for psoriasis such as Methotrexate, Ciclosporin, Acitretin, Etanercept, Adalimumab, Infliximab, and Ustekinumab.
•Prior history of phototherapy
•Past anaphylaxis history

发起方